JPIAMR supports research projects and networks that enable researchers to collaborate across national and scientific borders to find new treatments, solutions and methods to tackle AMR. It supports a large portfolio from 20 therapeutic candidates in the pipeline, to new knowledge on selection and transmission dynamics of AMR in a One Health context, the design of new interventions or new surveillance studies, standards and protocols.
Projects
Projects
JPIAMR supports research projects and networks that enable researchers to collaborate across national and scientific borders to find new treatments, solutions and methods to tackle AMR. It supports a large portfolio from 20 therapeutic candidates in the pipeline, to new knowledge on selection and transmission dynamics of AMR in a One Health context, the design of new interventions or new surveillance studies, standards and protocols.
Supported JPIAMR projects and networks
JPIAMR has coordinated 10 transnational joint calls till date supporting 61 projects and 38 networks with over 1170 researchers by investing 80 million Euros within the six priority areas of the shared JPIAMR Strategic Research and Innovation Agenda (SRIA) – therapeutics, diagnostics, surveillance, transmission, environment and interventions with a One Health approach.
Explore the JPIAMR project dashboard that presents interactive data on projects and networks supported under the various calls coordinated by the JPIAMR.
Click on the titles below for more information on the research activities and outcomes of the projects and the networks supported under the JPIAMR framework.
The JPIAMR six Priority topics are:
Transmission 
Environment 
Interventions 
Therapeutics 
Diagnostics 
Surveillance
Call
- All Calls
- Antimicrobial Resistance through the JPIAMR
- InnovaResistance: Innovative approaches to address antibacterial resistance
- AMR Networks/Working groups
- AMR Transmission Dynamics
- Prevention and Intervention Strategies to control AMR infections
- Innovations against antibiotic-resistant bacteria: New targets, compounds and tools
- JPIAMR Network Call on Surveillance
- JPIAMR-VRI Network Call 2018
- AMR Diagnostics and Surveillance
- JPIAMR Network Plus
Traditional and Complementary Medicine (T&CM) is often used in both animal and human healthcare and may contribute to reducing inappropriate antibiotic use (e.g. as part of delayed prescription strategies (human healthcare) or as alternative prevention or treatment (e.g. for uncomplicated acute infections in both human and animal healthcare).
Multiresistant bacteria are a severe problem to modern healthcare. The problem is increasing and development of novel technologies to cope with this critical situation is a necessity. Solutions include novel antibiotic drugs as well as reducing the spread of resistance genes in the environment.
The threat of AMR is rising in low and middle income countries (LMIC). The French Alliance of Health Sciences Research Institution (AVIESAN) has recently established a small network for AMR research in partnership with LMIC scientists to strengthen local research expertise. The aim is to assist in the collection of relevant evidence to advise stakeholders and policymakers on suitable control strategies for AMR reduction that are tailored to the local situation and founded on local problematics. Countries initially involved are Cambodia, Madagascar, Ivory Coast and France.
An integrated approach to surveillance spanning different sectors has been promoted by international organisations for more than a decade and constitutes a central recommendation of the WHO action plan on AMR. The objective of the CoEval-AMR Network is to develop consolidated guidance for evaluation that addresses the specific needs of integrated One Health surveillance systems for AMR and AMU.
The impact of antimicrobial resistance (AMR) is an almost invisible enemy, which slowly, but steadily has impacted society as a whole. Multi-, and/or pan-drug resistant strains have emerged, and have been spreading readily, causing deaths, disabilities and economic losses.
EPIC Alliance is composed of 11 members from 7 countries, bringing together experts from the fields of clinical and basic microbiology, infectious diseases, computational biology & chemistry, bioinformatics, biochemistry, translational biology, biophysics, pharmacology, toxicology, veterinary sciences, and epidemiology.
Main Questions/Approach: How can we best identify and promote collaboration and implementation between AMR NGS stakeholders that link the individual fields of (new) NGS technologies, algorithms, quality standards, teaching/training and sequence databanks?
Antibiotic overuse is contributing to rising rates of antimicrobial resistance. Audit and feedback (A&F) can be an effective tool to modify prescribing behaviour. Jurisdictions are, or will be, implementing community antibiotic A&F, as part of broader antimicrobial stewardship programs, which will benefit from tools and resources to optimize their effectiveness.
There is a growing recognition that interventions within the healthcare sector are not enough to curb antibiotic resistance development. Instead, a one-health perspective incorporating animal husbandry and external environments is needed. This calls for monitoring antibiotic resistance outside of the healthcare setting.
Early and specific detection of microbial infections is crucial for the containment of diseases and for reducing the dependence on the use of antibiotics. There is however a lack of reliable, cheap and easy to use detection methods for day-to-day monitoring of infection and antimicrobial resistances in samples from patients, animals and the environment. This deficinecy is critical for the abuse of antibiotics and the diffusion of antimicrobial resistance.
Blood stream infection (BSI) is annually responsible of hundred thousand estimated deaths worlwide. The time frame for identification and antimicrobial susceptibility testing of the causative agent(s) of BSI directly impact the delay in the administration of appropriate antimicrobial therapy and, consequently, the clinical outcome of patients.
Greater availability of fast and accurate diagnostics for infections would greatly reduce the over-prescription of antibiotics and slow the growth of antibiotic resistance which limits treatment options. It would also help prescribe the right drug at the right time, thus reducing suffering and increasing survival.
